UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma

World journal of gastroenterology : WJG, 2019-08, Vol.25 (29), p.3870-3896

2019

Volltextzugriff (PDF)

New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach

Cells (Basel, Switzerland), 2019-06, Vol.8 (6), p.584

2019

Volltextzugriff (PDF)

Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy

Drug resistance updates, 2015-05, Vol.20, p.39-70

2015

Volltextzugriff (PDF)

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions

International journal of molecular sciences, 2020-09, Vol.21 (17), p.6350

2020

Volltextzugriff (PDF)

Genetic Markers of the Host to Predict the Efficacy of Colorectal Cancer Targeted Therapy

Current medicinal chemistry, 2020-01, Vol.27 (25), p.4249-4273

2020

Volltextzugriff (PDF)

Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan

Journal of clinical oncology, 2009-05, Vol.27 (15), p.2457-2465

2009

Volltextzugriff (PDF)

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk

Biomedicine & pharmacotherapy, 2022-10, Vol.154, p.113644-113644, Article 113644

2022

Volltextzugriff (PDF)

The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices

Frontiers in neuroscience, 2020-11, Vol.14, p.603647-603647

2020

Volltextzugriff (PDF)

Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure

Biomedicine & pharmacotherapy, 2023-08, Vol.164, p.114906-114906, Article 114906

2023

Volltextzugriff (PDF)

Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer

Biomedicine & pharmacotherapy, 2023-11, Vol.167, p.115479-115479, Article 115479

2023

Volltextzugriff (PDF)

Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients' Management and Therapy Outcomes

International journal of molecular sciences, 2019-11, Vol.20 (21), p.5498

2019

Volltextzugriff (PDF)

Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis

International journal of molecular sciences, 2023-02, Vol.24 (4), p.3303

2023

Volltextzugriff (PDF)

Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2010-02, Vol.28 (5), p.866-871

2010

Volltextzugriff (PDF)

An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer

Frontiers in pharmacology, 2022-07, Vol.13, p.897951-897951

2022

Volltextzugriff (PDF)

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment

International journal of molecular sciences, 2017-07, Vol.18 (7), p.1522

2017

Volltextzugriff (PDF)

Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug-gene interactions

Frontiers in pharmacology, 2024-09, Vol.15, p.1420174

2024

Volltextzugriff (PDF)

Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC

Pharmaceutics, 2022-11, Vol.14 (11), p.2468

2022

Volltextzugriff (PDF)

Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy

Frontiers in pharmacology, 2020-06, Vol.11, p.897-897

2020

Volltextzugriff (PDF)

The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity

Human genomics, 2023-11, Vol.17 (1), p.1-99, Article 99

2023

Volltextzugriff (PDF)

Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients

Pharmacogenomics, 2019-11, Vol.20 (17), p.1179-1187

2019

Volltextzugriff (PDF)

Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment

Pharmacogenetics and genomics, 2013-10, Vol.23 (10), p.549-557

2013

Volltextzugriff (PDF)

Genetic biomarkers for hepatocellular cancer risk in a caucasian population

World journal of gastroenterology : WJG, 2017-09, Vol.23 (36), p.6674-6684

2017

Volltextzugriff (PDF)

Association of HLA-G 3′UTR Polymorphisms with Response to First-Line FOLFIRI Treatment in Metastatic Colorectal Cancer

Pharmaceutics, 2022-12, Vol.14 (12), p.2737

2022

Volltextzugriff (PDF)

HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment

PloS one, 2015-12, Vol.10 (12), p.e0144000-e0144000

2015

Volltextzugriff (PDF)

SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy

Frontiers in pharmacology, 2021-12, Vol.12, p.778781-778781

2021

Volltextzugriff (PDF)

1 – 25 von 336

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(311)
Mit Volltextzugriff
(297)

Publikationsform

Sprache

Englisch
(336)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma

New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach

Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions

Genetic Markers of the Host to Predict the Efficacy of Colorectal Cancer Targeted Therapy

Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk

The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices

Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure

Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer

Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients' Management and Therapy Outcomes

Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis

Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer

An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment

Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug-gene interactions

Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC

Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy

The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity

Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients

Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment

Genetic biomarkers for hepatocellular cancer risk in a caucasian population

Association of HLA-G 3′UTR Polymorphisms with Response to First-Line FOLFIRI Treatment in Metastatic Colorectal Cancer

HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment

SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy

Suchergebnisse filtern